Costs rose, inventories were high, and Sunflower Pharmaceutical's first-quarter performance both declined to “return to the original form”

Beginning in the fourth quarter of last year, the decline in both revenue and profit has already begun.

lanjinger.comMay 6 23:58

The indirect controlling shareholders of Huashen Technology (000790.SZ) increased their total shares by 1%

According to the Zhitong Finance App, Huashen Technology (000790.SZ) issued an announcement. As of the disclosure date of this announcement, the implementation period of this increase plan has passed. Chengdu Yuanhong Biotechnology Co., Ltd., the indirect controlling shareholder of the company, has increased its holdings of the company's shares by 6,280,000 shares through centralized bidding transactions through the Shenzhen Stock Exchange trading system, accounting for 1% of the current total share capital of the company, and the total amount paid is about 197636 million yuan. The current plan to increase its holdings has not yet been completed, and Chengdu Yuanhong will continue to increase its holdings in accordance with the holdings increase plan.

Zhitong FinanceMay 6 21:40

Lansheng Co., Ltd. (600826.SH) completed the repurchase of 2.15% of the shares at a cost of 100 million yuan

Lan Sheng Co., Ltd. (600826.SH) announced that as of May 6, 2024, the company's current share repurchase plan is actually...

Zhitong FinanceMay 6 21:06

RheinBio (002166.SZ): 1.08% of shares have been cumulatively repurchased

Gelonghui, May 6, 丨 Rhine Biotech (002166.SZ) announced that as of April 30, 2024, the total number of shares repurchased by the company through centralized bidding transactions through the stock repurchase special securities account was 7,992,071 shares, accounting for 1.08% of the company's total share capital. The maximum transaction price was 7.00 yuan/share, the minimum transaction price was 5.90 yuan/share, and the total transaction amount was RMB 49,9551 (excluding transaction fees).

Gelonghui FinanceMay 6 19:21

Jiangsu Wuzhong (600200): Losses have narrowed in 23 years and recently, Tongyan acupuncture has been on the market

Core view 24Q1: The steady increase in revenue in the pharmaceutical business helped increase revenue by 15%, and the performance was under pressure from investment in the medical and aesthetic business. The company's pharmaceutical business contributed the main revenue in '23, and some pharmaceutical products lost revenue due to withdrawal from medical insurance and national collection

中信建投證券May 6 18:46

Zhendong Pharmaceutical (300158.SZ) has repurchased 2.16% of its shares at a total cost of 103 million yuan

Zhendong Pharmaceutical (300158.SZ) announced that the company's repurchase has been completed. As of April 30, 2024, the company had repurchased a total of 22.174,900 shares of the company's shares, accounting for 2.16% of the company's total share capital, and the total transaction amount was 103 million yuan (excluding transaction fees).

Zhitong FinanceMay 6 18:37